Unsupervised principal component analysis with the main cancer invasiveness-enriched genes (ASPN, GLT8D2, OLFML2B, CRISPLD2, ADAM12, POSTN, and PRRX1) allowed for the discrimination of subgroups of BMAL1-dependent CRC patients (p = 9.9 × 10−4, Figure 1F). This evidence concerns the gene BMAL1 and cancer.